

The CONSORT reporting checklist

For checking that reports of randomised trials can be understood and used by everyone

How to use this reporting checklist

This reporting checklist allows authors to demonstrate that their manuscripts adhere to the [CONSORT reporting guideline](#).

If you have not used a reporting guideline before, read about [how and why to use them](#) and check whether CONSORT is the [most applicable reporting guideline](#) for your work.

Reporting guidelines are most useful when used early in research. When writing a manuscript or application, consider using the [full guidance](#) where you'll find explanations and examples for each item.

After writing, demonstrate adherence by completing this checklist:

1. Specify where each item is described (see [Note 1](#)).
2. Cite this checklist (See [Note 2](#)).
3. Include your completed checklist as a supplement when submitting to a journal so that future readers can use it to find information.

	Item Description	Location (or reason for not reporting)
Title and Abstract		
1a. Title	Identification as a randomised trial.	Title page.
1b. Structured Abstract	Structured summary of the trial design, methods, results, and conclusions.	Abstract.
Open Science		
2. Trial Registration	Name of trial registry, identifying number (with URL) and date of registration.	Abstract, Trial Registration; Declarations, Clinical Trial Registration.
Protocol and statistical analysis plan	Where the trial protocol and statistical analysis plan can be accessed.	Trial registration is provided in ClinicalTrials.gov. A separate publicly available protocol or statistical analysis plan was not reported.
4. Data sharing	Where and how the individual de-identified participant data (including data dictionary), statistical code and any other materials can be accessed.	Data Availability statement.

5. Funding and Conflicts of Interest		
5a. Funding	Sources of funding and other support (eg, supply of drugs), and role of funders in the design, conduct, analysis, and reporting of the trial.	Funding statement.
5b. Conflicts of interest	Financial and other conflicts of interest of the manuscript authors.	Conflict of Interest statement.
Introduction		
6. Background and rationale	Scientific background and rationale.	Introduction, paragraphs 1-4.
7. Objectives	Specific objectives related to benefits and harms.	Introduction, final paragraph.
Methods		
8. Patient and public involvement	Details of patient or public involvement in the design, conduct and reporting of the trial.	Not applicable; patients/public were not involved in the design, conduct, or reporting of the trial.
9. Trial Design	Description of trial design including type of trial (eg, parallel group, crossover), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory).	Methods, Study Design.
10. Changes to trial protocol	Important changes to the trial after it commenced including any outcomes or analyses that were not pre-specified, with reason.	No important changes to the trial protocol after commencement were reported.
11. Trial Setting	Settings (eg, community, hospital) and locations (eg, countries, sites) where the trial was conducted.	Methods, Ethical Approval; Methods, Study Design.
12. Eligibility Criteria		
12a. Participants	Eligibility criteria for participants.	Methods, Inclusion Criteria and Exclusion Criteria.
12b. Other	If applicable, eligibility criteria for sites and for individuals delivering the interventions (eg, surgeons, physiotherapists).	Methods, Surgical Procedure; all surgical procedures were performed according to a predetermined protocol.
13. Intervention and comparator	Intervention and comparator with sufficient details to allow replication. If relevant, where additional materials describing the intervention and comparator (eg, intervention manual) can be accessed.	Methods, Radiographic Evaluation; Methods, Surgical Procedure; Methods, Histopathological Evaluation; Methods, Immunohistochemical Analysis.
14. Outcomes	Prespecified primary and secondary outcomes,	Methods, Study Design;

	including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome.	Methods, Radiographic Evaluation; Methods, Immunohistochemical Analysis; Methods, Statistical Analysis.
15. Harms	How harms were defined and assessed (eg, systematically, non-systematically).	Results, Clinical and Radiological Outcomes; no implant loss or complications related to the sinus lifting procedure were observed.
16. Sample Size		
16a. How sample size was determined	How sample size was determined, including all assumptions supporting the sample size calculation.	Methods, Statistical Analysis.
16b. Interim analyses and stopping criteria	Explanation of any interim analyses and stopping guidelines.	Not applicable; no interim analyses or stopping criteria were planned or reported.
17. Randomisation		
17a. Sequence Generation	Who generated the random allocation sequence and the method used.	Methods, Study Design / randomization paragraph; the person generating the sequence is not specified.
17b. Type of Randomisation	Type of randomisation and details of any restriction (eg, stratification, blocking, and block size).	Methods, Study Design / randomization paragraph; 1:1:1 allocation ratio according to graft type.
18. Allocation concealment mechanism	Mechanism used to implement the random allocation sequence (eg, central computer/telephone; sequentially numbered, opaque, sealed containers), describing any steps to conceal the sequence until interventions were assigned.	Methods, Study Design / randomization paragraph; opaque, sequentially numbered, sealed envelope method.
19. Implementation	Whether the personnel who enrolled and those who assigned participants to the interventions had access to the random allocation sequence.	Methods, Study Design / randomization paragraph; envelopes were opened on the day of surgery after eligibility confirmation. Personnel access to the allocation sequence is not otherwise specified.
20. Blinding		
20a. Who was blinded	Who was blinded after assignment to interventions (eg, participants, care providers, outcome assessors, data analysts).	Methods, Radiographic Evaluation; Methods, Histopathological Analysis. Radiographic measurements

		were blinded between image sets, and histological/immunohistochemical evaluations were performed by a blinded examiner.
20b. How blinding was achieved	If blinded, how blinding was achieved and description of the similarity of interventions.	Methods, Radiographic Evaluation; Methods, Histopathological Analysis. Similarity of interventions was not applicable because different graft materials were compared.
21. Statistical methods		
21a. Comparing groups	Statistical methods used to compare groups for primary and secondary outcomes, including harms.	Methods, Statistical Analysis.
21b. Definition of who is included in each analysis	Definition of who is included in each analysis (e.g., all randomised participants), and in which group.	Methods, Study Design; Results, Clinical and Radiological Outcomes; Tables 2-6.
21c. Missing Data	How missing data were handled in the analysis.	Not reported; missing data handling was not specifically described.
21d. Additional Analyses	Methods for any additional analyses (eg, subgroup and sensitivity analyses), distinguishing pre-specified from post hoc.	Methods, Statistical Analysis; correlation analyses were described. No subgroup or sensitivity analyses were reported.
22. Participant flow, including flow diagram		
22a. Participant Numbers	For each group, the numbers of participants who were randomly assigned, received intended intervention, and were analysed for the primary outcome.	Results, Clinical and Radiological Outcomes; Tables 2-6.
22b. Losses and exclusions	For each group, losses and exclusions after randomisation, together with reasons.	Results, Clinical and Radiological Outcomes; losses/exclusions after randomisation are not fully described.
23. Recruitment		
23a. Dates	Dates defining the periods of recruitment and follow-	Not reported in the

	up for outcomes of benefits and harms.	manuscript.
23b. Reasons for stopping recruitment	If relevant, why the trial ended or was stopped.	Not applicable / not reported; the trial was not reported as being stopped early.
24. Intervention and comparator delivery		
24a. As Administered	Intervention and comparator as they were actually administered (eg, where appropriate, who delivered the intervention/comparator, whether participants adhered, whether they were delivered as intended (fidelity)).	Methods, Surgical Procedure.
24b. Concomitant Care	Concomitant care received during the trial for each group.	Methods, Surgical Procedure; postoperative medications and mouthwash protocol.
25. Baseline Data	A table showing baseline demographic and clinical characteristics for each group.	Results, Clinical and Radiological Outcomes.
26. Numbers analysed, outcomes, and estimation	For each primary and secondary outcome, by group: - the number of participants included in the analysis. - the number of participants with available data at the outcome time point. - result for each group, and the estimated effect size and its precision (such as 95% confidence interval). - for binary outcomes, presentation of both absolute and relative effect size.	Results, Clinical and Radiological Outcomes; Results, Histologic Outcomes; Tables 2-6.
27. Harms	All harms or unintended events in each group.	Results, Clinical and Radiological Outcomes; no implant loss or complications related to sinus lifting were observed; one unrelated anterior mandibular implant loss was reported.
28. Ancillary Analyses	Any other analyses performed, including subgroup and sensitivity analyses, distinguishing pre-specified from post hoc.	Not applicable; no ancillary subgroup or sensitivity analyses were reported.
Discussion		
29. Interpretation	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence.	Discussion; Conclusion.

30. Limitations	Trial limitations, addressing sources of potential bias, imprecision, generalisability, and, if relevant, multiplicity of analyses.	Discussion, final paragraphs / limitations.
-----------------	---	---

1 How to specify where content is

Tell the reader where they can find information. E.g.,

- Results; paragraph 2
- Methods, Participants; paragraphs 1 & 2.
- Table 3
- Supplement B, para. 4

If you have chosen not to describe an item, explain why. You can do this in the checklist, or as a note below it.

You can describe items in the article body, or in tables, figures, or supplementary materials, and should prioritize items you feel are most important to your intended audience. The order of items in your manuscript does not need to match the order of items in this checklist. You can decide how best to structure your work.

2 How to cite

Describe how you used CONSORT at the end of your Methods section, referencing the resources you used e.g.,

‘We used the CONSORT reporting guideline(1) to draft this manuscript, and the CONSORT reporting checklist(2) when editing, included in supplement A’

If you use a reporting checklist, remember to include it as a supplement when publishing so that readers can easily find information and see how you have interpreted the guidance.

1. Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, et al. CONSORT 2025 statement: Updated guideline for reporting randomised trials. The BMJ [Internet]. 2025 Apr;389:e081123. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11995449/>
2. Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, et al. The CONSORT reporting checklist. In: Harwood J, Albury C, Beyer J de, Schlüssel M, Collins G, editors. The EQUATOR network reporting guideline platform [Internet]. The UK EQUATOR Centre; 2025. Available from: <https://resources.equator-network.org/reporting-guidelines/consort/consort-checklist.docx>